- 2025 revenue +16.7%; IFRS gross profit +30.9%; gross margin up 5 percentage points to 46.0%; adjusted gross profit +25.5% YoY.
- Supported 945 integrated client projects as of Dec 31, 2025, including 74 in Phase III and 25 in commercial manufacturing.
- Adopted a digitally-native operating model leveraging computational modeling, predictive analytics and ontology-driven software to reduce manual bottlenecks.
- Rolled out a secure cloud client portal delivering real-time milestones, predictive data insights and synchronized program planning across manufacturing and quality metrics.
2025 financial performance
Revenue rose 16.7% year‑on‑year; IFRS gross profit increased 30.9%; gross profit margin expanded 5 percentage points to 46.0%; adjusted gross profit grew 25.5%, driven by momentum across research, development and manufacturing and improved operational efficiency.
Digital-native operations
WuXi Biologics says it rapidly transformed into a digitally-native operator by integrating computational modeling, predictive analytics and ontology-driven software; these intelligent systems reduced manual bottlenecks, shortened development timelines and improved transparency across the biologics lifecycle.
Client cloud portal
The company launched a secure cloud-based client portal providing a unified workspace with up-to-date milestones, predictive data insights, comprehensive program planning and fine-grained access controls, enabling near-real-time manufacturing, quality and inventory visibility, removing manual update cycles and aligning stakeholders on a single source of truth to accelerate progression from DNA to IND to BLA.
